Other
The content of this section is not part of the statutory audit of the annual financial statements but has undergone a separate limited assurance by our auditor.
The content of this section is voluntary, unaudited information, which was critically read by the auditor.
At a glance
€3,202 million
Sales
2024: €3,290 million
-€604 million
EBITDA before special items
2024: -€567 million
Sales in Other amounted to €3,202 million, below the prior-year level by €88 million. This was mainly due to lower sales in both commodity and energy trading.
EBITDA before special items of Other decreased slightly compared to the previous year. This was primarily due to increased LTI expenses and a lower earnings contribution from other businesses.
EBITDA in Other included special items of -€1,128 million in 2025. This included special charges in the amount of €595 million for restructuring measures as well as €328 million from the sale of BASF’s shares in the Nordlicht 1 and 2 wind farm projects.
Million € |
2025 |
2024 |
+/– |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales to third parties |
3,202 |
3,290 |
–2.7% |
|||||||||||||
EBITDA before special items |
–604 |
–567 |
–6.7% |
|||||||||||||
| of which costs for cross-divisional corporate research | –168 |
–183 |
8.3% |
|||||||||||||
costs of corporate headquarters |
–241 |
–232 |
–4.0% |
|||||||||||||
other businesses |
175 |
182 |
–3.9% |
|||||||||||||
miscellaneous income and expenses |
–371 |
–334 |
–11.0% |
|||||||||||||
Special items in EBITDA |
–1,128 |
–601 |
–87.7% |
|||||||||||||
EBITDA |
–1,732 |
–1,167 |
–48.4% |
|||||||||||||
Depreciation and amortizationb |
159 |
160 |
–0.9% |
|||||||||||||
EBIT before special items |
–752 |
–706 |
–6.5% |
|||||||||||||
Special items in EBIT |
–1,139 |
–622 |
–83.2% |
|||||||||||||
Income from operations (EBIT) |
–1,891 |
–1,328 |
–42.4% |
|||||||||||||
Investments including acquisitionsc |
131 |
240 |
–45.6% |
|||||||||||||
Assets (December 31)d |
18,299 |
19,647 |
–6.9% |
|||||||||||||
Research and development expenses |
254 |
276 |
–7.9% |
|||||||||||||
|
||||||||||||||||